What Blackrock Microsystems does

Blackrock Microsystems, Inc., operating as Blackrock Neurotech, is a privately held neurotechnology company headquartered in Salt Lake City, USA, founded in 2005. The company has developed a brain-computer interface (BCI) platform that decodes neural signals in real time, allowing patients with paralysis and other neurological disorders to control external devices through thought alone. Documented capabilities include typing at up to 90 characters per minute, decoding up to 62 words per minute from neural signals, and operating robotic arms, email clients, and creative software without physical input. The platform is backed by 19+ years of human studies, 30,000+ days of implant research, and 2,000+ peer-reviewed publications, giving it one of the deepest clinical evidence bases in the BCI field.

The company's revenue model operates along two customer tracks. The first is direct sales of neurotechnology devices (electrode arrays, recording systems, and supporting hardware/software) to research institutions; the company states it has equipped more than 1,000 laboratories at world-renowned universities and research centers worldwide. The second is the BCI Pioneer program, a direct-to-patient clinical engagement for individuals with paralysis and neurological disorders, supported by clinical partners. Pricing is not publicly disclosed, but the model resembles a high-value, low-volume medical device sale with multi-year capital and consumable streams. Marketing is conducted through owned digital channels (Twitter/X, LinkedIn, YouTube, Instagram, Facebook, newsletter, corporate website), with no evidence of third-party distribution or marketplace channels.

In May 2024, Blackrock filed a Form D with the SEC for an exempt securities offering of approximately $12.37 million involving multiple related persons and executive officers, indicating an active capital-raising posture. The company maintains an operational website (copyright 2026) and ongoing news output. The addressable market is supported by a third-party projection of a $0.95 billion BCI market by 2035. Revenue magnitude, profitability, unit pricing, and detailed customer economics are not disclosed in the available data, which limits financial diligence.

Name

Blackrock Microsystems

Legal name

Blackrock Microsystems, Inc.

Website

https://blackrockmicro.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

101–250 employees

Short description

Blackrock Microsystems (operating as Blackrock Neurotech) is a private Salt Lake City-based neurotechnology company that builds brain-computer interface systems enabling paralyzed patients to control devices via thought, and sells its BCI platform to over 1,000 research institutions globally.

Ownership category

akta.pro rank

Product category

Neurotechnology Devices

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Semiconductor and Other Electronic Component Manufacturing (3344)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Semiconductors & Related Devices (3674)

akta.pro primary industry

Compute & Acceleration ICs (CPU/GPU/AI/FPGA/ASIC) (HDAHABAC)

akta.pro secondary industry

Application Processors & Microprocessors (MPUs/CPUs) (HDAHAJAB)

Keywords

• Brain-computer interface
• Neurotechnology devices
• Neural signal processing
• Neuroprosthetic systems
• Neural recording platforms

Headquarters

HQ city

Salt Lake City

HQ country

India

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Distribution channels2 records

Marketing channels3 records

Core offering

Blackrock Microsystems (operating as Blackrock Neurotech) develops and manufactures brain-computer interface (BCI) neurotechnology platforms and devices. The company sells these neurotechnology devices to research institutions worldwide (equipping over 1,000 labs) and operates a BCI Pioneer program that enables patients with paralysis and neurological disorders to control external devices — including typing at up to 90 characters per minute and decoding up to 62 words per minute — through thought alone.

Product overview

Blackrock Neurotech offers a neurotechnology platform designed to improve patients' lives through brain-computer interface technology. The platform has enabled BCI Pioneers to perform daily activities such as eating, drinking, sending emails, and operating robotic arms by thinking. The company provides technology for research institutions (offering devices to over 1000 labs from world-renowned institutions) and for patients and clinicians. The platform supports capabilities including typing at up to 90 characters per minute and decoding up to 62 words per minute from thought.

Differentiator

Problem solved

Functional benefit

Products and services

• Neurotechnology Platform
• Research Neurotechnology Devices
• BCI Pioneer Patient Program

Quantifiable outcome

• Typing at up to 90 characters per minute using thought
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators6 records

Expansion highlights5 records

Direct peers

• Neuralink: Closest direct competitor developing implanted BCI devices for paralysis and communication; competes head-to-head with Blackrock in human BCI implants, though backed by significantly larger capital.
• Precision Neuroscience: Developer of a high-bandwidth cortical interface for paralyzed patients; competes in implanted BCI with overlapping neural decoding and motor-restoration use cases.
• NeuroPace: Commercial-stage neurotechnology company with the RNS System for responsive neurostimulation in epilepsy; overlaps as an implanted brain-interface device company targeting neurological disorders.
• Synchron: Implanted BCI company (Stentrode) targeting paralysis patients with a less-invasive vascular delivery approach; competes for the same clinical patient population as Blackrock.
• Paradromics: Fabless neurotechnology company building high-data-rate brain-computer interfaces; competes in the implanted neural recording and decoding category.

Emerging players

• Emotiv: Consumer- and research-grade EEG headset maker with overlap in the research-institution segment that Blackrock serves, though operating at the non-invasive, lower-bandwidth end of the market.
• Kernel: Non-invasive BCI and neuroimaging company using optical/MEG approaches; competes for the broader brain-computer interface opportunity, though with non-implanted technology.

Broad incumbents

• Boston Scientific: Diversified medical device incumbent with neuromodulation products; comparable in adjacent neurotech commercialization pathways and hospital-channel reach.
• Abbott: Medical device major with a neuromodulation division (formerly St. Jude) covering spinal cord and deep brain stimulation; comparable as a scaled channel for neuro-therapeutic devices.
• Medtronic: Large incumbent medical device company with deep-brain stimulation, neuromodulation, and neurosurgery franchises; overlaps with Blackrock in neurological therapeutic-device markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/blackrockmicro
• YouTubeyoutube.com/@BlackrockNeurotech
• Facebookfacebook.com/blackrockneuro
• LinkedInlinkedin.com/company/black-rock-neurotech/?original_referer=
• Instagraminstagram.com/blackrockneuro

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blackrock Microsystems